A Pilot Study to Examine the Effect of Egb761 on Plasma Biomarker Levels and on Cognitive Function in Patients With MCI
NCT ID: NCT07287852
Last Updated: 2025-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
PHASE2
50 participants
INTERVENTIONAL
2024-08-20
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Does drug Egb761 lower the plasma level of p-tau217 in patients with mild cognitive impairment? Does drug Egb761 improve cognitive and behavioral functions in these patients? Does Egb761 affect the blood levels of neurofilament-light (Nfl) and glial-fibrillary-acidic-protein (GFAP), which serve as additional biomarkers for brain disease activity?
Participants will:
Take Egb761 twice daily for 6 months Visit the clinic once every 3 months for checkups and tests Keep a diary of their symptoms
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patient recruitment: 50 patients with mild cognitive impairment (MCI) will be recruited, according to its accepted definition. Patients with MCI will undergo standard evaluation, including brain imaging (MRI / CT), thyroid function tests, Vitamin B12, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) to rule out other causes of cognitive decline.
The investigators expect that approximately 70% of recruited patients will display increased plasma p-tau217 level, indicating MCI of Alzheimer's type.
Clinical and neuropsychological evaluation will include: (1) Full demographic data (age, gender, education level and occupation, family status, ethnicity and country of origin); (2) Clinical data on risk factors (metabolic/ cardiovascular risk factors - heart disease, diabetes, hypertension, hyperlipidemia; Infectious/ inflammatory risk factors - periodontal disease, systemic infections, systemic inflammatory conditions; Lifestyle factors - smoking, alcohol consumption, sleeping disorder, physical activity; and Mental factors - anxiety and depression, cognitive activity); (3) MoCA (in Hebrew version); (4) Mild Behavioral Impairment checklist (MBI-C), or Neuropsychiatric Inventory (NPI) questionnaire (in Hebrew version); (5) ADL and iADL questionnaire; (6)Trail making test -B (TMT-B); Word fluency test.
Determination of blood biomarkers: Venous blood will be drawn upon recruitment in a tube containing EDTA to prevent clotting. The blood will be centrifuged at 1200 rpm for 5 minutes, and plasma stored in -80°C, within two hours of drawing the blood sample. The samples will be stored in a temperature-controlled and monitored freezer, until delivery in dry ice to the central lab (Prof. Ben-Hur's lab at the Ein-Kerem campus) for determination of biomarkers. Blood samples that were collected at recruitment will be tested for p-tau217 level, neurofilament light and GFAP. The baseline p-tau217 will serve as a reference value for monitoring individual response to therapy, as well as the group trend in the other biomarkers.
Treatment: All patients will receive Cerebonin (Egb761) 240mg per day, by tablets of 120mg, taken twice daily.
Follow-up: After initiation of treatment, patients will be invited for follow-up visits at 3 months and 6 months. Clinical data (risk factor assessment), MoCA, MBI-C, iADL and plasma p-tau217 level will be evaluated in each visit. The investigators will evaluate total MoCA score, as well as its breakdown into cognitive domains (attention, executive, memory (both free and cued / recognition recall), visuospatial, language, and orientation). One point is added if the subject has ≤12 years of education.
Evaluating response to therapy: (1) In patients with high baseline plasma p-tau181 level, the investigators will compare pre- and post-treatment plasma p-tau-217 levels (Δp-tau). Since plasma p-tau217 is considered a biomarker of active brain disease, a reduction in its level will suggest a disease-modifying therapeutic effect; (2) The investigators will examine the trend in group averages of neurofilament and GFAP, as additional disease biomarkers. (3) The investigators will determine the symptomatic clinical response according to improvement in MoCA, MBI-C/NPI, TMT-B and ADL/iADL scores after 3 and 6 months of treatment; (4) The investigators will compare the treatment effect in MCI patients with high- versus normal- plasma p-tau217 levels (eg. in MCI of AD type versus non-AD type); (5) The investigators will examine the association between clinical improvement and change in the plasma level of biomarkers.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A single arm trial, where all participants will receive the studied medication
In this single arm trial, the post-treatment biomarkers levels will be compared to pre-treatment levels per participant, with each participant's pre-treatment biomarkers' levels serving as baseline for reference.
Ginkgo Biloba Extract 761
Each participant will receive two 120mg Egb761 pills per day along the 6 month trial
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ginkgo Biloba Extract 761
Each participant will receive two 120mg Egb761 pills per day along the 6 month trial
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Preserved instrumental activities of daily life (iADL).
Exclusion Criteria
* Active cancer, severe cardio-pulmonary disease or other medical condition which negatively affects ability to evaluate patients and complete follow-up.
* Inability to sign an informed consent due to psychiatric or dementing condition.
* Hypersensitivity to any ingredient of the study medication.
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hadassah Medical Organization
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hadassah medical Center
Jerusalem, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0658-22-HMO
Identifier Type: -
Identifier Source: org_study_id